SCHEMBL309261

SCHEMBL309261

O=Cc1ccc(N(c2ccc(C=O)cc2)c2ccc(C=O)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.65
ALDH1A3 P47895 3/20 0.65
ALDH3A1 P30838 1/20 0.65
CYP2A6 P11509 4/20 0.64
CYP2A13 Q16696 1/20 0.64
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 1/20 0.50
ALDH5A1 P51649 1/20 0.50
ABAT P80404 1/20 0.50
TYR P14679 1/20 0.44
EGFR P00533 1/20 0.39
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
PTGS2 P35354 1/20 0.39
RAB9A P51151 1/20 0.39
STS P08842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29258833 1.00 ALDH1A1 (0.65) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL3181855 0.92 ALDH1A1 (0.58) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL19313178 0.92 ALDH1A1 (0.58) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL806381 0.92 ALDH1A1 (0.58) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL3181867 0.92 ALDH1A1 (0.58) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL13808643 0.92 ALDH1A1 (0.58) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL181026 0.90 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL2199745 0.90 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL851178 0.90 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13
SCHEMBL13649928 0.90 ALDH1A1 (0.59) ALDH1A1ALDH1A3ALDH3A1CYP2A6CYP2A13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117718078-B Hydrophilic covalent organic framework catalyst for stably anchoring transition metal ions and preparation method and application thereof CHINA UNIVERSITY OF PETROLEUM (EAST CHINA) (CN) 2026-05-26 CN claimed
CN-122076269-A Covalent organic framework mixed matrix membrane, in-situ growth method thereof and application thereof in ion separation 2026-05-26 CN claimed
CN-122032347-A Covalent organic framework-based heavy metal ion separation membrane and preparation method and application thereof 中国科学院青岛生物能源与过程研究所 2026-05-15 CN claimed
US-12534498-B2 Compounds for use as apelin receptor antagonists CAMBRIDGE ENTERPRISE LIMITED (GB) 2026-01-27 US claimed
CN-115931823-B In-situ preparation method of flexible SERS substrate based on nano film 陕西师范大学 2025-05-30 CN claimed
CN-120054631-A Selective hydrogenation catalyst and preparation method thereof 中国石油天然气股份有限公司 2025-05-30 CN claimed
CN-120058460-A Hydrogenation method for carbon one-to-carbon three-fraction 中国石油天然气股份有限公司 2025-05-30 CN claimed
CN-119978364-A Triphenylamine imidazole porous organic polymer, preparation method thereof and application thereof in proton conduction and photocatalysis antibiosis 山东大学 2025-05-13 CN claimed
CN-119954681-A Small molecule photocrosslinker, preparation method and application 南京工业大学 2025-05-09 CN claimed
CN-117463325-B Alkyne selective hydrogenation catalyst and preparation method thereof 中国石油天然气股份有限公司 2025-04-25 CN claimed
EP-1957605-B1 ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2017-01-11 EP claimed
US-9018409-B2 Process for functionalization of unsaturated compounds MEURICE R&D ASBL (BE) 2015-04-28 US claimed
US-8591997-B2 Process for preparing structured organic films (SOFS) via a pre-SOF XEROX CORPORATION (US) 2013-11-26 US claimed
EP-2632886-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS Meurice R&D ASBL (BE) 2013-09-04 EP claimed
US-20130211033-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS MEURICE R&D ASBL (BE) 2013-08-15 US claimed
US-8304095-B2 Organic electroluminescent devices MERCK PATENT GMBH (DE) 2012-11-06 US claimed
WO-2012055946-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS MEURICE R&D ASBL (BE) 2012-05-03 WO claimed
US-20080272693-A1 Organic Electroluminescent Devices MERCK PATENT GMBH (DE) 2008-11-06 US claimed
EP-1957605-A1 ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2008-08-20 EP claimed
WO-2007065549-A1 ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2007-06-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12534498-B2 Compounds for use as apelin receptor antagonists APLNR, NPBWR1, AP3B1 ALDH1A1 4464/4885ALDH1A3 4721/4885ALDH3A1 4503/4885
US-20130211033-A1 PROCESS FOR FUNCTIONALIZATION OF UNSATURATED COMPOUNDS F10, RPP30, PUF60 ALDH1A1 46/4885ALDH1A3 106/4885ALDH3A1 60/4885
US-20080272693-A1 Organic Electroluminescent Devices EML4, MT-ND4L, EPCAM ALDH1A1 600/4885ALDH1A3 237/4885ALDH3A1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.